দেশ: আয়ার্লণ্ড
ভাষা: ইংরেজি
সূত্র: HPRA (Health Products Regulatory Authority)
APRACLONIDINE HYDROCHLORIDE
Alcon Laboratories (UK) Ltd
S01EA03
APRACLONIDINE HYDROCHLORIDE
1 %w/v
Eye Drops Solution
Product subject to prescription which may not be renewed (A)
Sympathomimetics in glaucoma therapy
Authorised
1996-05-21
Please replace with: SA Alcon-Couvreur NV Rijksweg 14, B-2870 Puurs, Belgium. Please update to November 2015 Please replace with: Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system (see details below). By reporting side effects you can help provide more information on the safety of this medicine. United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/ yellowcard Ireland HPRA Pharmacovigilance Earlsfort Terrace IRL - Dublin 2 Tel: +353 1 6764971 Fax: +353 1 6762517 Website: www.hpra.ie e-mail: medsafety@hpra.ie. সম্পূর্ণ নথি পড়ুন
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT IOPIDINE 1%w/v Eye Drops, Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Apraclonidine 1% w/v (10mg/ml) (as hydrochloride). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Eye drops, solution IOPIDINE 1% is a pale yellow solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS IOPIDINE 1% is indicated to control or prevent post surgical elevations in intraocular pressure that occur in patients after anterior segment laser surgery. (Clinical trials have been conducted in trabeculoplasty, iridotomy and capsulotomy). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS (INCLUDING THE ELDERLY): One drop of IOPIDINE 1% should be instilled into the eye scheduled for operation one hour before initiating anterior segment laser surgery. A second drop should be instilled into the same eye immediately upon completion of the laser surgical procedure. If for any reason, the drop of IOPIDINE 1% does not remain in the eye, repeat the dose by placing another drop in the eye. Nasolacrimal occlusion or gently closing the eyelid after instillation is recommended. This may reduce the systemic absorption of medications administered via the ocular route and result in a decrease in systemic side effects. There are no special precautions for administration to the elderly. CHILDREN: Safety and effectiveness of IOPIDINE in children have not been established and therefore IOPIDINE 1% is not recommended for use in children. 4.3 CONTRAINDICATIONS IOPIDINE 1% is contraindicated in patients with a history of severe or unstable and uncontrolled cardiovascular disease. IOPIDINE 1% is contraindicated for children, for patients receiving monoamine oxidase inhibitor therapy, systemic sympathomimetic agents, tricyclic antidepress সম্পূর্ণ নথি পড়ুন